US approves new drug to treat Alzheimer’s

Fri, 2023-01-06 20:25

WASHINGTON: The US Food and Drug Administration on Friday approved a highly anticipated new drug designed to slow cognitive decline in patients in the early stages of Alzheimer’s disease.
The FDA approval of the drug, Leqembi, also known as lecanemab, came just days after the agency was harshly criticized in a congressional report for its green-lighting of another Alzheimer’s drug, Aduhelm.
And it was granted despite trial results showing the monoclonal antibody treatment carries risks of brain swelling and bleeding.

Main category: 


See also  Ukraine, US-China relations dominate Asia security meeting in Singapore

This website uses cookies. By continuing to use this site, you accept our use of cookies.